GLPwatch
Papers (10373)
Page 39 of 173, ranked by citation count.
- Cardiovascular outcomes with semaglutide by severity of chronic kidney disease in type 2 diabetes: the FLOW trial.
- Comparative persistence and adherence with newer anti-hyperglycemic agents to treat patients with type 2 diabetes in the United States.
- The once-daily human GLP-1 analogue liraglutide impacts appetite and energy intake in patients with type 2 diabetes after short-term treatment.
- Characterization of liraglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, in rat partial and full nigral 6-hydroxydopamine lesion models of Parkinson's disease.
- Liraglutide: a review of its use in adult patients with type 2 diabetes mellitus.
- Assessing patient PREFERence between the dulaglutide pen and the semaglutide pen: A crossover study (PREFER).
- Pancreatic beta cell function following liraglutide-augmented weight loss in individuals with prediabetes: analysis of a randomised, placebo-controlled study.
- Semaglutide reduces fat accumulation in the tongue: A randomized single-blind, pilot study.
- Potential Roles of Glucagon-Like Peptide 1 Receptor Agonists (GLP-1 RAs) in Nondiabetic Populations.
- Liraglutide Reduces Both Atherosclerosis and Kidney Inflammation in Moderately Uremic LDLr-/- Mice.
- Enhancing human islet transplantation by localized release of trophic factors from PLG scaffolds.
- Dosing rationale for liraglutide in type 2 diabetes mellitus: a pharmacometric assessment.
- Effect of dulaglutide in promoting abstinence during smoking cessation: 12-month follow-up of a single-centre, randomised, double-blind, placebo-controlled, parallel group trial.
- MondoA Is an Essential Glucose-Responsive Transcription Factor in Human Pancreatic β-Cells.
- Glucagon-like peptide-1 receptor agonist exendin-4 mitigates lipopolysaccharide-induced inflammatory responses in RAW264.7 macrophages.
- Liraglutide prevents beta-amyloid-induced neurotoxicity in SH-SY5Y cells via a PI3K-dependent signaling pathway.
- Effects of semaglutide on risk of cardiovascular events across a continuum of cardiovascular risk: combined post hoc analysis of the SUSTAIN and PIONEER trials.
- The role of basal insulin and glucagon-like peptide-1 agonists in the therapeutic management of type 2 diabetes--a comprehensive review.
- The Impact of Glucagon-like Peptide 1 Receptor Agonists on Obstructive Sleep Apnoea: A Scoping Review.
- Activation of GLP-1 receptor enhances the chemosensitivity of pancreatic cancer cells.
- Long-Acting Neurotensin Synergizes With Liraglutide to Reverse Obesity Through a Melanocortin-Dependent Pathway.
- Do current incretin mimetics exploit the full therapeutic potential inherent in GLP-1 receptor stimulation?
- Combination Therapy With Canagliflozin Plus Liraglutide Exerts Additive Effect on Weight Loss, but Not on HbA<sub>1c</sub>, in Patients With Type 2 Diabetes.
- Long-acting amylin analogues for the management of obesity.
- In vitro and in vivo evaluation of a once-weekly formulation of an antidiabetic peptide drug exenatide in an injectable thermogel.
- GLP-1 receptor agonists as promising anti-inflammatory agents in heart failure with preserved ejection fraction.
- Seven glucagon-like peptide-1 receptor agonists and polyagonists for weight loss in patients with obesity or overweight: an updated systematic review and network meta-analysis of randomized controlled trials.
- Trends in use of sodium-glucose co-transporter 2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1RA) in Australia in the era of increased evidence of their cardiovascular benefits (2014-2022).
- Liraglutide for the treatment of obesity among patients with hidradenitis suppurativa.
- Dulaglutide and cardiovascular and heart failure outcomes in patients with and without heart failure: a post-hoc analysis from the REWIND randomized trial.
- Differentiating among incretin therapies: a multiple-target approach to type 2 diabetes.
- Liraglutide, leptin and their combined effects on feeding: additive intake reduction through common intracellular signalling mechanisms.
- Glucagon-Like Peptide-1 Receptor Agonists for Type 2 Diabetes: A Clinical Update of Safety and Efficacy.
- Time course of cardiometabolic alterations in a high fat high sucrose diet mice model and improvement after GLP-1 analog treatment using multimodal cardiovascular magnetic resonance.
- Improvements in health-related quality of life with liraglutide 3.0 mg compared with placebo in weight management.
- Novel GLP-1/GLP-2 co-agonists display marked effects on gut volume and improves glycemic control in mice.
- Exenatide has a pronounced effect on energy intake but not energy expenditure in non-diabetic subjects with obesity: A randomized, double-blind, placebo-controlled trial.
- Liraglutide: a review of its use in the management of obesity.
- Effects of a Dulaglutide plus Calorie-Restricted Diet versus a Calorie-Restricted Diet on Visceral Fat and Metabolic Profiles in Women with Polycystic Ovary Syndrome: A Randomized Controlled Trial.
- Indirect comparison of glucagon like peptide-1 receptor agonists regarding cardiovascular safety and mortality in patients with type 2 diabetes mellitus: network meta-analysis.
- Obesity pharmacotherapy: incretin action in the central nervous system.
- Does combining liraglutide with intragastric balloon insertion improve sustained weight reduction?
- Exendin-4 ameliorates cardiac ischemia/reperfusion injury via caveolae and caveolins-3.
- GLP-1 Analogue Liraglutide Attenuates Mutant Huntingtin-Induced Neurotoxicity by Restoration of Neuronal Insulin Signaling.
- Durability of protective effect of dulaglutide on pancreatic β-cells in diabetic mice: GLP-1 receptor expression is not reduced despite long-term dulaglutide exposure.
- GLP-1RAs caused gastrointestinal adverse reactions of drug withdrawal: a system review and network meta-analysis.
- Semaglutide reduces tumor burden in the GAN diet-induced obese and biopsy-confirmed mouse model of NASH-HCC with advanced fibrosis.
- Evaluation of exenatide versus insulin glargine for the impact on endothelial functions and cardiovascular risk markers.
- The incretin hormones: from scientific discovery to practical therapeutics.
- Tirzepatide versus semaglutide for weight loss in patients with type 2 diabetes mellitus: A value for money analysis.
- Development of a reliable automated screening system to identify small molecules and biologics that promote human β-cell regeneration.
- Use of Liraglutide 3.0 mg for Weight Management in a Real-World Setting in Switzerland.
- Effects of incretin-based therapeutic agents including tirzepatide on renal outcomes in patients with type 2 diabetes: A systemic review and meta-analysis.
- Sequential induction of beta cell rest and stimulation using stable GIP inhibitor and GLP-1 mimetic peptides improves metabolic control in C57BL/KsJ db/db mice.
- p38<i>β</i> Mitogen-Activated Protein Kinase Signaling Mediates Exenatide-Stimulated Microglial <i>β</i>-Endorphin Expression.
- Improved diastolic function in type 2 diabetes after a six month liraglutide treatment.
- GLP-1/Exendin-4 induces β-cell proliferation via the epidermal growth factor receptor.
- Review article: role of glucagon-like peptide-1 receptor agonists in non-alcoholic steatohepatitis, obesity and diabetes-what hepatologists need to know.
- Comparison of the effects of 10 GLP-1 RA and SGLT2 inhibitor interventions on cardiovascular, mortality, and kidney outcomes in type 2 diabetes: A network meta-analysis of large randomized trials.
- Exenatide improves ovarian and endometrial injury and preserves ovarian reserve in streptozocin induced diabetic rats.